| Molecular formula | C28H40N4O8S2 |
| Molecular weight | 624.8 g/mol |
| Registered trials | 8 |
| PubChem CID | 6450830 |
What MK-677 Is
MK-677, also known as Ibutamoren, is a synthetic compound with the molecular formula C28H40N4O8S2 and a molecular weight of about 624.8 g/mol (PubChem CID 6450830). It does not have an approved drug label from any regulatory agency, and it is classified as an unapproved research compound. No FDA-sanctioned indications, dosing standards, or mechanism-of-action statements exist for it in official labeling.
Trial Footprint
Clinicaltrials.gov lists 8 registered trials involving MK-677. Sampled studies include a completed Phase 2 trial examining Ibutamoren's impact on nonalcoholic fatty liver disease (NCT05364684) and a completed Phase 2 trial evaluating an oral growth hormone secretagogue drug for fibromyalgia (NCT00116129). Another completed trial studied the effect of the growth hormone secretagogue MK-0677 on IGF-1 levels in patients with end-stage renal disease (NCT00395291). These entries describe study design and status only, not outcomes or efficacy.
FAQ
No. MK-677, also called Ibutamoren, has no FDA-approved label and is classified as an unapproved research compound. There is no official indication, dosing guidance, or mechanism statement from a regulatory body for this substance.
Registered trials have examined MK-677 in contexts such as nonalcoholic fatty liver disease, fibromyalgia, and IGF-1 levels in patients with end-stage renal disease. These are research studies and do not establish that the compound is safe or effective for any use.
Clinicaltrials.gov lists 8 registered trials involving this compound as of the most recent data pull. The available sample includes completed Phase 2 studies and one trial without a specified phase.
Yes, Ibutamoren is another name used for MK-677 in scientific literature and trial registrations, including under the designation MK-0677. Both names refer to the same compound (PubChem CID 6450830).
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 6450830 ClinicalTrials.gov (NCT05364684, NCT00116129, NCT00395291)
Updated 2026-09-26